Welcome to the UPF Digital Repository

Sustained seropositivity up to 20.5 months after COVID-19

Show simple item record

dc.contributor.author Dobaño, Carlota
dc.contributor.author Ramírez-Morros, Anna
dc.contributor.author Alonso, Selena
dc.contributor.author Rubio, Rocío
dc.contributor.author Ruiz-Olalla, Gemma
dc.contributor.author Vidal Alaball, Josep
dc.contributor.author Macià, Dídac
dc.contributor.author Miró Catalina, Queralt
dc.contributor.author Vidal, Marta
dc.contributor.author Fuster Casanovas, Aina
dc.contributor.author Prados de la Torre, Esther
dc.contributor.author Barrios, Diana
dc.contributor.author Jiménez, Alfons
dc.contributor.author Zanoncello, Jasmina
dc.contributor.author Rodrigo Melero, Natalia
dc.contributor.author Carolis, Carlo
dc.contributor.author Izquierdo, Luis
dc.contributor.author Aguilar, Ruth
dc.contributor.author Moncunill, Gemma
dc.contributor.author Ruiz-Comellas, Anna
dc.date.accessioned 2023-01-18T07:34:54Z
dc.date.available 2023-01-18T07:34:54Z
dc.date.issued 2022
dc.identifier.citation Dobaño C, Ramírez-Morros A, Alonso S, Rubio R, Ruiz-Olalla G, Vidal-Alaball J, Macià D, Catalina QM, Vidal M, Casanovas AF, Prados de la Torre E, Barrios D, Jiménez A, Zanoncello J, Melero NR, Carolis C, Izquierdo L, Aguilar R, Moncunill G, Ruiz-Comellas A. Sustained seropositivity up to 20.5 months after COVID-19. BMC Med. 2022 Oct 13;20(1):379. DOI: 10.1186/s12916-022-02570-3
dc.identifier.issn 1741-7015
dc.identifier.uri http://hdl.handle.net/10230/55322
dc.description.abstract This study evaluated the persistence of IgM, IgA, and IgG to SARS-CoV-2 spike and nucleocapsid antigens up to 616 days since the onset of symptoms in a longitudinal cohort of 247 primary health care workers from Barcelona, Spain, followed up since the start of the pandemic. The study also assesses factors affecting antibody levels, including comorbidities and the responses to variants of concern as well as the frequency of reinfections. Despite a gradual and significant decline in antibody levels with time, seropositivity to five SARS-CoV-2 antigens combined was always higher than 90% over the whole study period. In a subset of 23 participants who had not yet been vaccinated by November 2021, seropositivity remained at 95.65% (47.83% IgM, 95.65% IgA, 95.65% IgG). IgG seropositivity against Alpha and Delta predominant variants was comparable to that against the Wuhan variant, while it was lower for Gamma and Beta (minority) variants and for IgA and IgM. Antibody levels at the time point closest to infection were associated with age, smoking, obesity, hospitalization, fever, anosmia/hypogeusia, chest pain, and hypertension in multivariable regression models. Up to 1 year later, just before the massive roll out of vaccination, antibody levels were associated with age, occupation, hospitalization, duration of symptoms, anosmia/hypogeusia, fever, and headache. In addition, tachycardia and cutaneous symptoms associated with slower antibody decay, and oxygen supply with faster antibody decay. Eight reinfections (3.23%) were detected in low responders, which is consistent with a sustained protective role for anti-spike naturally acquired antibodies. Stable persistence of IgG and IgA responses and cross-recognition of the predominant variants circulating in the 2020-2021 period indicate long-lasting and largely variant-transcending humoral immunity in the initial 20.5 months of the pandemic, in the absence of vaccination.
dc.description.sponsorship The study received support from the Fundació Privada Daniel Bravo Andreu. Development of SARS-CoV-2 RBD was partially supported by the NIAID CEIRS contract HHSN272201400008C. L.I. work was supported by PID2019-110810RB-I00. E.P. was supported by a grant from the Junta de Andalucía/EU. R.R. had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). ISGlobal receives support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. Funders were not involved in the study conduct, manuscript preparation, or submission.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher BioMed Central
dc.relation.ispartof BMC Med. 2022 Oct 13;20(1):379
dc.rights © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data ma
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Sustained seropositivity up to 20.5 months after COVID-19
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1186/s12916-022-02570-3
dc.subject.keyword Antibody
dc.subject.keyword COVID-19
dc.subject.keyword Duration
dc.subject.keyword Health care workers
dc.subject.keyword IgA
dc.subject.keyword IgG
dc.subject.keyword IgM
dc.subject.keyword Kinetics
dc.subject.keyword SARS-CoV-2
dc.subject.keyword Seroprevalence
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PID2019-110810RB-I00
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking